Nucleotides can be
synthesized by a variety of means, both
in vitro and
in vivo. In vitro,
protecting groups may be used during laboratory production of nucleotides. A purified
nucleoside is protected to create a
phosphoramidite, which can then be used to obtain analogues not found in nature and/or to
synthesize an oligonucleotide. In vivo, nucleotides can be synthesized
de novo or recycled through
salvage pathways. The components used in de novo nucleotide synthesis are derived from biosynthetic precursors of carbohydrate and
amino acid metabolism, and from ammonia and carbon dioxide. Recently it has been also demonstrated that cellular bicarbonate metabolism can be regulated by
mTORC1 signaling. The liver is the major organ of de novo synthesis of all four nucleotides. De novo synthesis of pyrimidines and purines follows two different pathways. Pyrimidines are synthesized first from aspartate and carbamoyl-phosphate in the cytoplasm to the common precursor ring structure orotic acid, onto which a phosphorylated ribosyl unit is covalently linked. Purines, however, are first synthesized from the sugar template onto which the ring synthesis occurs. For reference, the syntheses of the
purine and
pyrimidine nucleotides are carried out by several enzymes in the
cytoplasm of the cell, not within a specific
organelle. Nucleotides undergo breakdown such that useful parts can be reused in synthesis reactions to create new nucleotides.
Pyrimidine ribonucleotide synthesis . The synthesis of the pyrimidines
cytidine triphosphate (CTP) and
uridine triphosphate (UTP) occurs in the cytoplasm and starts with the formation of
carbamoyl phosphate from
glutamine and CO2. Next,
aspartate carbamoyltransferase catalyzes a condensation reaction between
aspartate and carbamoyl phosphate to form
carbamoyl aspartic acid, which is cyclized into
4,5-dihydroorotic acid by
dihydroorotase. The latter is converted to
orotate by
dihydroorotate oxidase. The net reaction is: :(
S)-Dihydroorotate + O2 → Orotate + H2O2 Orotate is covalently linked with a phosphorylated ribosyl unit. The covalent linkage between the ribose and pyrimidine occurs at position C1 of the
ribose unit, which contains a
pyrophosphate, and N1 of the pyrimidine ring.
Orotate phosphoribosyltransferase (PRPP transferase) catalyzes the net reaction yielding
Orotidine 5'-monophosphate (OMP): :Orotate +
5-Phospho-α-D-ribose 1-diphosphate (PRPP) → Orotidine 5'-phosphate + Pyrophosphate Orotidine 5'-monophosphate is decarboxylated by
orotidine-5'-phosphate decarboxylase to form
uridine monophosphate (UMP). PRPP transferase catalyzes both the ribosylation and decarboxylation reactions, forming UMP from orotic acid in the presence of PRPP. It is from UMP that other pyrimidine nucleotides are derived. UMP is phosphorylated by two kinases to uridine triphosphate (UTP) via two sequential reactions with ATP. First, the diphosphate from UDP is produced, which in turn is phosphorylated to UTP. Both steps are fueled by ATP hydrolysis: :ATP + UMP → ADP + UDP :UDP + ATP → UTP + ADP CTP is subsequently formed by the amination of UTP by the catalytic activity of
CTP synthetase. Glutamine is the NH3 donor and the reaction is fueled by ATP hydrolysis, too: :UTP + Glutamine + ATP + H2O → CTP + ADP + Pi
Cytidine monophosphate (CMP) is derived from cytidine triphosphate (CTP) with subsequent loss of two phosphates.
Purine ribonucleotide synthesis The atoms that are used to build the
purine nucleotides come from a variety of sources: origins of purine ring
atoms'''N1 arises from the amine group of
AspC2 and C8 originate from
formateN3 and N9 are contributed by the amide group of
GlnC4, C5 and N7 are derived from
Gly C6 comes from HCO3− (CO2) The
de novo synthesis of
purine nucleotides by which these precursors are incorporated into the purine ring proceeds by a 10-step pathway to the branch-point intermediate
IMP, the nucleotide of the base
hypoxanthine.
AMP and
GMP are subsequently synthesized from this intermediate via separate, two-step pathways. Thus, purine
moieties are initially formed as part of the
ribonucleotides rather than as
free bases. Six enzymes take part in IMP synthesis. Three of them are multifunctional: •
GART (reactions 2, 3, and 5) •
PAICS (reactions 6, and 7) •
ATIC (reactions 9, and 10) The pathway starts with the formation of
PRPP.
PRPS1 is the
enzyme that activates
R5P, which is formed primarily by the
pentose phosphate pathway, to PRPP by reacting it with
ATP. The reaction is unusual in that a pyrophosphoryl group is directly transferred from ATP to C1 of R5P and that the product has the
α configuration about C1. This reaction is also shared with the pathways for the synthesis of
Trp,
His, and the
pyrimidine nucleotides. Being on a major metabolic crossroad and requiring much energy, this reaction is highly regulated. In the first reaction unique to purine nucleotide biosynthesis,
PPAT catalyzes the displacement of PRPP's
pyrophosphate group (PPi) by an amide nitrogen donated from either
glutamine (N),
glycine (N&C),
aspartate (N),
folic acid (C1), or CO2. This is the committed step in purine synthesis. The reaction occurs with the inversion of configuration about ribose C1, thereby forming
β-
5-phosphorybosylamine (5-PRA) and establishing the anomeric form of the future nucleotide. Next, a glycine is incorporated fueled by ATP hydrolysis, and the carboxyl group forms an amine bond to the NH2 previously introduced. A one-carbon unit from folic acid coenzyme N10-formyl-THF is then added to the amino group of the substituted glycine followed by the closure of the imidazole ring. Next, a second NH2 group is transferred from glutamine to the first carbon of the glycine unit. A carboxylation of the second carbon of the glycin unit is concomitantly added. This new carbon is modified by the addition of a third NH2 unit, this time transferred from an aspartate residue. Finally, a second one-carbon unit from formyl-THF is added to the nitrogen group and the ring is covalently closed to form the common purine precursor inosine monophosphate (IMP). Inosine monophosphate is converted to adenosine monophosphate in two steps. First, GTP hydrolysis fuels the addition of aspartate to IMP by adenylosuccinate synthase, substituting the carbonyl oxygen for a nitrogen and forming the intermediate adenylosuccinate. Fumarate is then cleaved off forming adenosine monophosphate. This step is catalyzed by adenylosuccinate lyase. Inosine monophosphate is converted to guanosine monophosphate by the oxidation of IMP forming xanthylate, followed by the insertion of an amino group at C2. NAD+ is the electron acceptor in the oxidation reaction. The amide group transfer from glutamine is fueled by ATP hydrolysis.
Pyrimidine and purine degradation In humans, pyrimidine rings (C, T, U) can be degraded completely to CO2 and NH3 (urea excretion). That having been said, purine rings (G, A) cannot. Instead, they are degraded to the metabolically inert
uric acid which is then excreted from the body. Uric acid is formed when GMP is split into the base guanine and ribose. Guanine is deaminated to xanthine which in turn is oxidized to uric acid. This last reaction is irreversible. Similarly, uric acid can be formed when AMP is deaminated to IMP from which the ribose unit is removed to form hypoxanthine. Hypoxanthine is oxidized to xanthine and finally to uric acid. Instead of uric acid secretion, guanine and IMP can be used for recycling purposes and nucleic acid synthesis in the presence of PRPP and aspartate (NH3 donor). ==Quantification of dNTP pools==